Prothena Corporation plc (PRTA)
$9.33
$0.24
(2.64%)
As on 28-Aug-2026 13:37EDT
Market cap
$485 Mln
Revenue (TTM)
$55 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
51,336,974
10 Years Aggregate
CFO
$-623.32 Mln
EBITDA
$-954.62 Mln
Net Profit
$-942.58 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Prothena (PRTA)
| -2.3 | 7.2 | -7.0 | 9.0 | -44.2 | -32.8 | -15.5 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Prothena (PRTA)
| -31.0 | -39.7 | 22.0 | 311.3 | -24.1 | 53.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Prothena (PRTA)
|
9.3 | 485.1 | 54.5 | -44.0 | -80.0 | -15.5 | -- | 1.7 |
| 47.8 | 8,108.0 | 1,667.7 | 66.1 | 9.4 | 3.6 | 127.2 | 4.5 | |
| 27.9 | 2,045.5 | 0.0 | -62.3 | -- | -19.5 | -- | 5.5 |
Shareholding Pattern
View DetailsAbout Prothena (PRTA)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized... monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland. Read more
-
President, CEO & Director
Dr. Gene G. Kinney Ph.D.
-
President, CEO & Director
Dr. Gene G. Kinney Ph.D.
-
Headquarters
Dublin
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Prothena (PRTA)
What is the current share price of Prothena Corporation plc (PRTA) Today?
The share price of Prothena Corporation plc (PRTA) is $9.33 (NASDAQ) as of 28-Aug-2026 13:37 EDT. Prothena Corporation plc (PRTA) has given a return of -44.21% in the last 3 years.
What is the current PB & PE ratio of Prothena Corporation plc (PRTA)?
Since, TTM earnings of Prothena Corporation plc (PRTA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.11 |
1.83 |
2024 |
-6.09 |
1.53 |
2023 |
-13.26 |
3.47 |
2022 |
-27.81 |
5.23 |
2021 |
34.38 |
4.94 |
What is the 52 Week High and Low of Prothena Corporation plc (PRTA)?
The 52-week high and low of Prothena Corporation plc (PRTA) are Rs 11.80 and Rs 7.73 as of 30-Aug-2026.
What is the market cap of Prothena Corporation plc (PRTA)?
Prothena Corporation plc (PRTA) has a market capitalisation of $ 485 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Prothena Corporation plc (PRTA)?
Before investing in Prothena Corporation plc (PRTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.